Researchers advance a new oral therapy to fight pancreatic fibrosis

Working with cultured cells and an animal model, investigators at Saint Louis University have been advancing work on a new drug that may have the potential for fighting pancreatic fibrosis.

A protein known as transforming growth factor beta (or TGFB) spurs fibrogenesis--described as a "series of cellular actions that cause overproduction of collagen and its resulting scarring."

Using an integrin inhibitor they blocked a gene necessary for TGFB to occur, preventing fibrosis in their animal models while also showing they could shutter the gene in cultured cells.


Accelerate Clinical Operations Across Sponsors, CROs and Partners With a Best-of-Breed Partner Like Box

Tuesday, March 24 | 11am ET / 8am PT

Learn how Box is a critical force multiplier in the Best-of-Breed application stack with partners like Nintex, DocuSign and Slack in supporting clinical operations for both regulated and non-regulated content.

Now they plan to go on with more work in the field, studying how their inhibitor may impact other cells in the pancreas while working on an oral version of their therapy.

"Although the understanding of the causes of chronic pancreatitis and pancreatic cancer have advanced in the past decade, neither the incidence nor the outcome from these diseases has changed--indicating that large gaps in knowledge remain that have prevented the development of effective preventive and treatment measures," said David Griggs, senior author and director of biology at Saint Louis University's Center for World Health and Medicine.

"In this paper we identified a group of proteins as new and important players in the mechanism of pancreatic fibrogenesis. Using a mouse model of chronic pancreatitis developed in SLU's laboratory, we demonstrated that small molecular compounds developed by SLU's Center for World Health and Medicine can very rapidly arrest the fibrosis process even after it is well underway in the organ."

- here's the release
- get the journal article

Suggested Articles

German scientists are targeting a protein-cutting enzyme that many viruses, including the coronavirus COVID-19, need to replicate.

UPenn scientists found blocking the Wnt/beta-catenin pathway in endothelial cells made chemotherapy more effective in mouse models of glioblastoma.

Astellas’ Xospata and Novartis’ Rydapt may help treat lung cancer that has grown resistant to EGFR inhibitors, researchers discovered.